Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Craneware Plc

Healthcare GB CRW

1470.0GBX
-5.0(0.34%)

Last update at 2026-03-10T15:47:00Z

Day Range

1450.001520.00
LowHigh

52 Week Range

1362.752621.14
LowHigh

Fundamentals

  • Previous Close 1475.00
  • Market Cap539.73M
  • Volume108781
  • P/E Ratio37.07
  • Dividend Yield2.54%
  • EBITDA30.02M
  • Revenue TTM211.33M
  • Revenue Per Share TTM6.03
  • Gross Profit TTM 182.06M
  • Diluted EPS TTM0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 23.98M 15.75M 13.09M 13.10M 13.16M
Minority interest - - - - -
Net income 19.66M 11.70M 9.23M 9.41M 12.90M
Selling general administrative - - 20.38M 20.38M 9.30M
Selling and marketing expenses - - 15.27M 15.27M 6.62M
Gross profit 179.27M 162.20M 148.44M 142.37M 70.20M
Reconciled depreciation - 33.38M 32.16M 29.40M 5.24M
Ebit 25.35M 20.88M 17.38M 20.24M 19.73M
Ebitda 38.80M 54.26M 49.54M 49.64M 24.97M
Depreciation and amortization 13.45M 33.38M 32.16M 29.40M 5.24M
Non operating income net other - - - - -
Operating income 25.25M 19.73M 19.23M 18.13M 13.24M
Other operating expenses 180.41M 169.53M 156.85M 145.11M 55.80M
Interest expense 1.27M 5.13M 6.36M 5.03M 0.08M
Tax provision - 4.04M 3.85M 3.69M 0.26M
Interest income - 1.14M 0.21M 0.00100M 0.00100M
Net interest income - -3.98700M -6.14300M -5.03000M -0.07500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.32M 4.04M 3.85M 3.69M 0.26M
Total revenue 205.66M 189.27M 174.02M 165.54M 75.58M
Total operating expenses 154.02M 142.46M 131.28M 121.93M 50.43M
Cost of revenue 26.38M 27.07M 25.58M 23.18M 5.37M
Total other income expense net -1.27300M -3.98700M -6.65300M -7.13600M -6.56200M
Discontinued operations - - - - -
Net income from continuing ops - 11.70M 9.23M 9.41M 12.90M
Net income applicable to common shares - - 9.23M 9.41M 12.90M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 551.06M 543.65M 576.98M 568.79M 311.60M
Intangible assets 185.73M 202.23M 216.56M 230.69M 31.92M
Earning assets - - - - -
Other current assets 8.36M 4.14M 41.25M 41.25M 19.43M
Total liab 213.50M 215.06M 249.13M 235.77M 51.32M
Total stockholder equity 337.56M 328.59M 327.84M 333.02M 260.28M
Deferred long term liab - - - 0.03M 1.69M
Other current liab 148.41M 131.81M 0.14M 0.02M 0.43M
Common stock 0.66M 0.66M 0.66M 0.66M 0.62M
Capital stock - 0.66M 0.66M 0.66M 0.62M
Retained earnings 44.27M 39.34M 39.88M 42.24M 46.83M
Other liab - - 44.45M 48.17M 0.76M
Good will 235.24M 235.24M 235.24M 237.65M 11.19M
Other assets - - 2.76M 3.23M 10.89M
Cash 55.92M 34.59M 78.54M 47.16M 235.62M
Cash and equivalents - - - - -
Total current liabilities 181.11M 148.76M 127.38M 82.51M 49.41M
Current deferred revenue - 16.86M 113.85M 58.70M 32.19M
Net debt -24.26700M 5.56M 8.15M 65.93M -234.46900M
Short term debt 28.64M 8.95M 9.39M 8.00M 1.05M
Short long term debt - 8.00M 8.00M 8.00M -
Short long term debt total 31.65M 40.15M 86.69M 113.08M 1.15M
Other stockholder equity 94.40M 92.71M -40.54400M -42.89500M -47.45200M
Property plant equipment - - 8.46M 8.82M 2.55M
Total current assets 119.59M 93.23M 113.96M 88.41M 255.05M
Long term investments - - - - -
Net tangible assets - - -123.95200M -135.31100M 217.17M
Short term investments - - - - -
Net receivables 55.31M 54.49M 24.17M 35.31M 17.04M
Long term debt - 27.37M 75.03M 103.59M -
Inventory - -7.78700M - - -
Accounts payable 4.06M 3.73M 4.00M 15.79M 15.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 198.23M 195.88M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.62M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.25M 4.37M -460.25700M 3.23M -45.66200M
Deferred long term asset charges - - - - -
Non current assets total 431.47M 450.43M 463.01M 480.39M 56.55M
Capital lease obligations - 4.78M 3.66M 1.50M 1.15M
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -15.81400M -15.33700M -307.32000M -10.32500M
Change to liabilities - - -5.46200M -13.50000M 4.20M
Total cashflows from investing activities -13.98500M -15.81400M -15.33700M -307.32000M -10.32500M
Net borrowings - -48.00000M -30.55200M 109.97M -0.96400M
Total cash from financing activities -24.58100M -69.99600M -53.28200M 91.90M 174.55M
Change to operating activities - - 50.55M 50.55M 50.55M
Net income 19.66M 15.75M 13.09M 13.10M 13.16M
Change in cash 21.33M -43.94800M 31.38M -188.46000M 187.77M
Begin period cash flow 34.59M 78.54M 47.16M 235.62M 47.85M
End period cash flow 55.92M 34.59M 78.54M 47.16M 235.62M
Total cash from operating activities 59.90M 41.86M 98.75M 26.96M 23.54M
Issuance of capital stock - 0.28M -0.04100M 1.49M 187.33M
Depreciation 34.21M 33.38M 32.16M 29.40M 5.24M
Other cashflows from investing activities -13.49400M -14.62300M 0.21M 0.00100M 0.00100M
Dividends paid 13.27M 12.80M 12.12M 12.98M 9.70M
Change to inventory - - - - -
Change to account receivables -7.07300M -21.18300M 1.12M -3.20300M 2.03M
Sale purchase of stock -0.10500M -3.34800M -3.81500M -1.72600M -0.42200M
Other cashflows from financing activities -2.34700M -6.12600M -9.30700M 116.09M 184.25M
Change to netincome - - 11.15M 4.85M -0.83400M
Capital expenditures 0.49M 16.96M 15.55M 14.03M 10.33M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.97M -4.01400M 46.20M -16.70200M 6.22M
Stock based compensation 5.70M 4.49M 2.99M 2.12M 2.14M
Other non cash items -0.64200M -7.74100M 6.14M 5.03M 0.07M
Free cash flow 59.41M 24.91M 83.20M 12.93M 13.21M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRW
Craneware Plc		 -5.0 0.34% 1470.00 37.07 12.84 2.55 2.16 3.42 11.56
COG
Cambridge Cognition Holdings Plc		 0.50 1.23% 41.00 - 14.16 2.19 8.48 2.30 100.23
RENX
Renalytix AI plc		 0.05 1.61% 3.15 - - 6.44 8.06 3.81 -0.2835
FDBK
Feedback PLC		 -0.185 1.40% 13.06 - - 9.56 0.89 2.29 -0.8995
TRLS
Trellus Health plc		 -0.037 7.05% 0.49 3.25 - 275.30 0.30 19.80 1.06

Reports Covered

Stock Research & News

View All

Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged data. In addition, it provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, the company offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.

Craneware Plc

1 Tanfield, Edinburgh, United Kingdom, EH3 5DA

Key Executives

Name Title Year Born
Mr. Keith Neilson Co-Founder, CEO & Exec. Director 1969
Mr. Craig Thomas Preston ACA CFO, Company Sec. & Exec. Director 1971
Ms. Isabel Urquhart Chief People Officer & Director 1968
Mr. Abhilesh Gandhi Group Chief Technology Officer NA
Mr. Derek William Paterson Chief Information Officer 1968
Mr. Eric Carter Chief Legal Officer NA
Mr. Mark Montgomery Chief Marketing Officer NA
Mr. Seth Droe Chief Revenue Officer NA
Ms. Karen Bowden RHIA Exec. VP of Customer Management NA
Ms. Lidia A. Rodriguez-Hupp Chief Customer Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.